The Influence of Mitochondrial Derived Reactive Oxygen Species on Cardiovascular Health in Patients With Chronic Obstructive Pulmonary Disease
Overview
- Phase
- Early Phase 1
- Intervention
- MitoQ
- Conditions
- Chronic Obstructive Pulmonary Disease
- Sponsor
- Virginia Commonwealth University
- Enrollment
- 4
- Locations
- 1
- Primary Endpoint
- Change in Skeletal Muscle Oxygenation
- Status
- Terminated
- Last Updated
- last year
Overview
Brief Summary
Cardiovascular health is a critical problem in patients with chronic obstructive pulmonary disease (COPD). Existing literature suggests oxidative stress from the mitochondria c driving some of the poor health outcomes in COPD. MitoQ is a mitochondrial-targeted antioxidant that has shown promise in improving cardiovascular outcomes in similar populations. Thus the purpose of this study is to test if MitoQ can improve cardiovascular health in COPD.
Detailed Description
In this study, a mitochondria-specific antioxidant will be compared to a placebo. Participants will be assigned randomly to receive either the antioxidant or the placebo for 6 weeks. A comprehensive assessment of cardiovascular health will be conducted before and after the administration of the supplement.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Clinically diagnosed of COPD
- •Global Initiative for obstructive lung disease (GOLD) Stages II to IV
Exclusion Criteria
- •Forced Expiratory Volume in 1 second/ Functional Vital Capacity (FEV1/FVC) \>0.7
- •Heart Disease
- •Vasoactive medications
- •Uncontrolled high blood pressure
- •Fluid in lungs
- •Sleep apnea
- •Raynaud's Phenomenon
- •Gangrene of the digits
- •History of coagulation
- •Pregnant women
Arms & Interventions
MitoQ
Participants will take 1 pill each day for 6 weeks
Intervention: MitoQ
Placebo
Participants will take 1 pill each day for 6 weeks
Intervention: Placebo
Outcomes
Primary Outcomes
Change in Skeletal Muscle Oxygenation
Time Frame: Baseline and 6 weeks
Near-infrared spectroscopy will be used to measure leg muscle oxygenation
Change in vascular function
Time Frame: Baseline and 6 weeks
Flow-mediated dilation will be used to measure vasodilation in the brachial artery
Change in oxidative stress
Time Frame: Baseline and 6 weeks
Blood draws will be taken to measure oxidative stress markers in the blood through electron paramagnetic resonance
Secondary Outcomes
- Change in arterial stiffness(Baseline and 6 weeks)
- Change in microvascular function(Baseline and 6 weeks)